ArticleMolecular biology reports2025
The role of visfatin and omentin-1 gene polymorphism in pancreatic ductal adenocarcinoma (PDAC).
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPancreatic ductal adenocarcinoma is a highly aggressive digestive system tumor with a poor prognosis. It is characterized by aggressive features and non-specific early symptoms, often leading to detection only after metastasis has occurred.
objectivesTo investigate the role of visfatin rs4730153 and omentin-1 rs2274907 gene polymorphisms in susceptibility to pancreatic cancer, while evaluating their serum levels and correlating these levels with clinical, laboratory, and pathological data. SUBJECTS AND
methodsThis study involved 192 participants, including 96 native pancreatic cancer patients with confirmed histopathological examinations and 96 age- and gender-matched controls. All individuals underwent a comprehensive medical history assessment, physical examination, and ultrasound imaging. Serum levels of visfatin, omentin-1, and tumor markers were measured using ELISA techniques. Genotyping of visfatin (rs4730153) and omentin (rs2274907) polymorphisms was conducted using quantitative fluorescent PCR.
resultsThe GG genotype and G allele of rs4730153 were significantly more prevalent in the patient group, with odds ratios of 4.154 and 1.711, respectively. Additionally, vascular invasion, poor survival, and a progressive disease course were significantly more common in the AG and GG genotypes. The distribution of omentin-1 rs2274907 indicated that higher serum visfatin levels, larger tumor sizes, vascular invasion, metastasis, poor survival, and lower serum omentin-1 levels were significantly more prevalent in the AT and TT genotypes.
conclusionThe visfatin rs4730153 gene polymorphism is associated with susceptibility to pancreatic cancer, vascular invasion, a progressive disease course, and poor survival outcomes. In contrast, the omentin-1 rs2274907 polymorphism is linked to tumor size, vascular invasion, metastasis, and overall survival.
Indexed as
Identifiers
40668426What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.